- Source: Nisa Leung
Nisa Leung (Chinese:梁颕宇 or 梁颖宇) is a venture capitalist and managing partner at Qiming Venture Partners. She has been named on the Forbes Midas List for six consecutive years since 2019. and ranked top 2 in Best Women Venture Capitalists by Forbes China for three successive years since 2021. She was awarded The Fortune Most Powerful Women Asia (MPW Asia) in 2024 by Fortune Asia and The Most Powerful Women in Business by Fortune China from 2022 to 2024. Nisa is widely known as China's leading investor in healthcare.
Education
Nisa earned a Bachelor of Science degree from Cornell University and graduated from Stanford Graduate School of Business in 2001 with an MBA.
Career
Nisa started her career in healthcare investment after realizing there was a lack of advanced therapeutics in China when her family was seeking treatments for her distant uncle, who was diagnosed with liver cancer.
Prior to joining Qiming Venture Partners in 2006, she co-founded Biomedic Holdings, which had operations and investments in medical devices, pharmaceuticals, and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). She was also Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.
Nisa sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), Caidya, Belief BioMed, Alamar Biosciences, Pluslife, Horizone, SinoUnited Health among others. Her other investments include Gan & Lee (SSE:603087), Cansino Biologics (SSE:688185; HKSE:6185), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Schrödinger (NASDAQ:SDGR) , Structure Therapeutics (NASDAQ:GPCR), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Apollomics (NASDAQ:APLM), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed, Novast, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), MedX, Goodwill (SSE:688246), Insilico Medicine, Jacobio (HKSE:1167), Hope Medicine, Chain Medical Labs, Sinotau, Zencore Biologics, Cognitact, Silicon Gene, Vision Pro, Thorough Future among others.
Nisa is recognized as playing a key role in China's biotech boom and innovation.
She serves as Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited. She is also a visiting lecturer at Harvard Law School, Stanford University International Advisory Council member, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA. . Nisa is also the Chair of Future Forum in 2023-2024.
References
Kata Kunci Pencarian:
- RGM-79 GM
- Nisa Leung
- List of Stanford GSB alumni
- Qiming Venture Partners
- Sophie Leung
- 2017 National People's Congress election in Hong Kong
- Hidayat Inayat Khan
- List of documentary films
- Soto ayam
- Fidelity Investments
- List of pen names
